Prostaglandins and aspirin therapy in Bartter's syndrome.
A young patient with Bartter's syndrome was treated for three months with 100 mg/kg/day of aspirin to inhibit prostaglandin synthesis. Clinical symptoms resolved and serum-potassium increased from 2-9 to 3-5 mmol/l. Urinary excretion and plasma concentration of prostaglandins E and F were significantly reduced during aspirin therapy. Plasma-renin activity declined from 85 to 20 ng/ml/h (normal 1-5-4 mg/ml/h) and hyperaldosteronism was corrected. These results suggest that overproduction of prostaglandins has a central role in the pathogenesis of Bartter's syndrome.
D000450:Aldosterone / Q000652:urine; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001477:Bartter Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D001835:Body Weight; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy*; D007223:Infant; D011188:Potassium / Q000378:metabolism; D011453:Prostaglandins / Q000096:biosynthesis / Q000378:metabolism*; D011458:Prostaglandins E / Q000037:antagonists & inhibitors / Q000378:metabolism; D011460:Prostaglandins F / Q000037:antagonists & inhibitors / Q000378:metabolism; D012083:Renin / Q000097:blood
D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D000450:Aldosterone; D012083:Renin; D001241:Aspirin; D011188:Potassium